| Cabozantinib | BSC |  |
---|---|---|---|
Utilities | |||
 | Utility gain | Utility gain | Incremental utility |
Stable LY | 0.646 | 0.341 | 0.305 |
Progressive LY | 0.505 | 0.632 | −0.127 |
Total | 1.151 | 0.973 | 0.178 |
Stable QALY | 0.491 | 0.259 | 0.232 |
Progressive QALY | 0.343 | 0.429 | −0.086 |
Total | 0.834 | 0.698 | 0.146 |
 | Costs in $ (%a) | Costs in $ (%a) | Incremental costs (%a) |
Costs Germany | |||
 Cabozantinib | 53,018 (93.6) | 0 (0.0) | 53,018 (97.2) |
 Adverse events | 1607 (2.8) | 375 (18.2) | 1232 (2.3) |
 Consultation | 513 (0.9) | 434 (21.0) | 69 (0.1) |
 Laboratory | 202 (0.4) | 173 (8.4) | 29 (< 0.1) |
 Imaging | 1281 (2.3) | 1083 (52.5) | 198 (0.4) |
 Total | 56,621 (100.0) | 2064 (100.0) | 54,556 (100.0) |
Costs United States | |||
 Cabozantinib | 167,288 (94.6) | 0 (0.0) | 167,288 (96.8) |
 Adverse events | 6030 (3.8) | 1075 (56.2) | 4955 (2.9) |
 Consultation | 1075 (0.6) | 914 (43.8) | 161 (0.1) |
 Laboratory | 868 (0.3) | 751 (0.0) | 117 (0.1) |
 Imaging | 2236 (0.7) | 1890 (0.0) | 346 (0.2) |
 Total | 177,496 (100.0) | 4630 (100.0) | 172,866 (100.0) |